Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T/TCR-T Immunotherapy for Solid Malignancies
NCT03941626Phase 2Unknown
- Sponsor
- BinDeBio
- Start
- Sep 2019
- Primary completion
- May 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of NY-ESO-1 CAR-T, DR5 CAR-T, EGFRvIII CAR-T, mesothelin CAR-T in esophageal cancer, hepatocellular carcinoma (HCC), glioblastoma (GBM), gastric cancer (GC), sponsored by BinDeBio. Status: unknown.
02
Drugs
NY-ESO-1 CAR-TDR5 CAR-TEGFRvIII CAR-Tmesothelin CAR-T
03
Conditions
esophageal cancerhepatocellular carcinoma (HCC)glioblastoma (GBM)gastric cancer (GC)
Beyond the preview
Go deeper on NCT03941626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941626.